Impact of serum interleukin-18 level as a prognostic indicator in patients with epithelial ovarian carcinoma

被引：27

作者：

Akahira J.-I. ^{[1
]}

Konno R. ^{[1
]}

Ito K. ^{[1
]}

Okamura K. ^{[1
]}

Yaegashi N. ^{[1
]}

机构：

[1] Department of Obstetrics, Tohoku Univ. Grad. Sch. of Medicine, Aoba-ku, Sendai 980-8574

来源：

International Journal of Clinical Oncology | 2004年 / 9卷 / 1期

关键词：

IL-18; Ovarian cancer; Prognostic factor;

D O I：

10.1007/s10147-003-0360-6

中图分类号：

学科分类号：

摘要：

Background. Interleukin-18 (IL-18), a cytokine produced by macrophages, is capable of inducing T-lymphocyte synthesis of interferon-γ (IFN-γ). In this study, for the first time, the serum concentration of IL-18 and its significance as a prognostic indicator was evaluated in patients with epithelial ovarian cancer. Methods. The serum IL-18 level was measured by an enzyme-linked immunosorbent assay (ELISA) in 69 patients with epithelial ovarian cancer and 8 healthy controls. Relationships between the IL-18 level and clinicopathological features were examined by univariate and multivariate analyses. Results. The median serum IL-18 level in the ovarian cancer patients was 229.6 pg/ml, and the level was significantly elevated compared with that in the normal controls (151.3 pg/ml; P < 0.01). No significant correlations were detected between the IL-18 level and stage or histology (P = 0.08 and P = 0.12, respectively). On univariate analysis, overall survival was shown to be affected by IL-18 serum levels. However, multivariate analysis failed to demonstrate an independent prognostic significance for IL-18 serum levels, while confirming the role of previously established prognostic variables, such as performance status, stage, and residual tumor. Conclusion. This study showed that IL-18 serum levels were elevated in ovarian cancer patients and were correlated with overall survival, although they were shown not to be an independent prognostic factor.

引用

页码：42 / 46

页数：4

共 32 条

[1]

Nakashima N., Nagasaka T., Fukata S., Et al., Study of ovarian tumors treated at Nagoya University Hospital, 1965-1988, Gynecol Oncol, 37, pp. 103-111, (1993)

[2]

Boring C.C., Squires T.S., Tong T., Et al., Cancer Statistics, CA Cancer J Clin, 44, pp. 7-26, (1994)

[3]

Young R.C., Chabner B.A., Hubbard S.P., Et al., Advanced ovarian adenocarcinoma: A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy, N Engl J Med, 299, pp. 1261-1266, (1978)

[4]

Redman J.R., Petrini G.R., Saigo P.E., Et al., Prognostic factors in advanced ovarian carcinoma, J Clin Oncol, 4, pp. 515-523, (1986)

[5]

Heintz A.P.M., Hacker N.F., Berek J.S., Et al., Cytoreductive surgery in ovarian carcinoma: Feasibility and morbidity, Obstet Gynecol, 67, pp. 783-788, (1986)

[6]

Omura G.A., Brady M.F., Homesley H.D., Et al., Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience, J Clin Oncol, 9, pp. 1138-1150, (1991)

[7]

Del Campo J.M., Felip E., Rubio D., Et al., Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment, Gynecol Oncol, 53, pp. 27-32, (1994)

[8]

Borden E.C., Chin P., Interleukin-6: A cytokine with potential diagnostic and therapeutic roles, J Lab Clin Med, 123, pp. 824-829, (1994)

[9]

Zeisler H., Tempfer C., Joura E.A., Et al., Serum interleukin 1 in ovarian cancer patients, Eur J Cancer, 34, pp. 931-933, (1998)

[10]

Foti E., Ferrandina G., Martucci R., Et al., IL-6, M-CSF and IAP cytokines in ovarian cancer: Simultaneous assessment of serum levels, Oncology, 57, pp. 211-215, (1999)

← 1 2 3 4 →